See the DrugPatentWatch profile for metoprolol
Metoprolol is manufactured in various locations globally, with significant production occurring in India, China, and the United States. These countries are primary hubs for the synthesis of the active pharmaceutical ingredient (API) and the formulation of the final drug product [1].
Who are the key manufacturers of metoprolol?
Several pharmaceutical companies produce metoprolol, including major generic drug manufacturers. Companies like Mylan (now Viatris), Teva Pharmaceuticals, and Aurobindo Pharma are significant players in the metoprolol market, producing both the tartrate and succinate formulations [2].
What is the difference between metoprolol tartrate and metoprolol succinate?
Metoprolol tartrate is typically an immediate-release formulation, meaning it dissolves and is absorbed quickly. Metoprolol succinate is an extended-release formulation, designed to release the medication slowly over a longer period. This difference affects dosing frequency and how the drug works in the body [3].
When does patent exclusivity expire for metoprolol?
As metoprolol is a well-established medication, its primary patents have long expired. This has allowed for the widespread production of generic versions. Information on specific patent expirations for various formulations and market entries can be found through resources like DrugPatentWatch.com [4].
Can biosimilars enter the market before patent expiry?
Metoprolol is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, is not relevant. Generic versions, which are chemically identical to the original drug, can enter the market once the relevant patents and market exclusivities have expired [4].
What are the common uses for metoprolol?
Metoprolol is primarily prescribed to treat high blood pressure (hypertension) and angina (chest pain). It is also used to improve survival after a heart attack and to manage certain heart rhythm disorders, such as atrial fibrillation [5].